NCT03623529 - A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

April 30, 2023

Conditions

Catecholamine-resistant Hypotension (CRH)Distributive ShockHigh Output ShockSeptic Shock

Interventions

DRUG

LJPC-501 (angiotensin II)

Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.

DRUG

Placebo

Placebo Arm

Trial Locations (2)

NOT_YET_RECRUITING

Investigational Site, Brussels

RECRUITING

Investigational Site, Vilnius